Euro vs US Dollar

Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.

Registrieren

KAPA Kairos Pharma Ltd

1,7251

0,7551 (77,85%)

Zuletzt aktualisiert: 16:59:58

Verzögert um 15 Minuten

Form 3 - Initial statement of beneficial ownership of securities

Kairos Pharma (AMEX:KAPA)
Historical Stock Chart
Von Dez 2024 bis Jan 2025

Click Here for more Kairos Pharma Charts.

Kairos Pharma (AMEX:KAPA)
Historical Stock Chart
Von Jan 2024 bis Jan 2025

Click Here for more Kairos Pharma Charts.

News Kairos Pharma Ltd

Kairos Pharma to Present at the Lytham Partners Investor Healthcare Summit
Dienstag 7 Januar 2025 (6 Tage vor) • Business Wire

Form 8-K - Current report
Freitag 13 Dezember 2024 (1 Monat vor) • Edgar (US Regulatory)

Kairos Pharma Adds City of Hope Cancer Center for Phase 2 ENV105 Clinical Trial
Dienstag 3 Dezember 2024 (1 Monat vor) • Business Wire

Form 8-K - Current report
Dienstag 19 November 2024 (2 Monate vor) • Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Donnerstag 14 November 2024 (2 Monate vor) • Edgar (US Regulatory)

Form 8-K - Current report
Donnerstag 10 Oktober 2024 (3 Monate vor) • Edgar (US Regulatory)

Form 8-K - Current report
Freitag 4 Oktober 2024 (3 Monate vor) • Edgar (US Regulatory)

Form S-8 - Securities to be offered to employees in employee benefit plans
Freitag 27 September 2024 (4 Monate vor) • Edgar (US Regulatory)

Form 8-K - Current report
Freitag 27 September 2024 (4 Monate vor) • Edgar (US Regulatory)

Form 3 - Initial statement of beneficial ownership of securities
Mittwoch 25 September 2024 (4 Monate vor) • Edgar (US Regulatory)

Form 8-K - Current report
Dienstag 24 September 2024 (4 Monate vor) • Edgar (US Regulatory)

Form 8-K - Current report
Dienstag 17 September 2024 (4 Monate vor) • Edgar (US Regulatory)

Weitere Kairos Pharma Ltd News-Artikel

DJ Sweden Total Stock Ma...

Amundi Etf Istoxx Eur P ...

ARK 21Shares Blockchain ...

BNP Paribas Issuance

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen